Precision Targeted Therapy with BLU-667 for <i>RET</i>-Driven Cancers
Vivek Subbiah(The University of Texas MD Anderson Cancer Center), Erica Evans(Blueprint Medicines (United States)), Marcia S. Brose(University of Pennsylvania), Michelle Maynard(Blueprint Medicines (United States)), Christoph Lengauer(Blueprint Medicines (United States)), Steven P. Miller(University of British Columbia), Lori J. Wirth(Harvard University), Matthew H. Taylor(Providence Portland Medical Center), Paul Fleming(Blueprint Medicines (United States)), Qiongfang Cao(Blueprint Medicines (United States)), Timothy J. Guzi(Blueprint Medicines (United States)), Michael Palmer(Blueprint Medicines (United States)), Elena Garralda(Memorial Sloan Kettering Cancer Center), Rami Rahal(Blueprint Medicines (United States)), Beni B. Wolf(Blueprint Medicines (United States)), Michael P. Sheets(Blueprint Medicines (United States)), Justin F. Gainor(Massachusetts General Hospital), Mimi I. Hu(The University of Texas MD Anderson Cancer Center), Sai‐Hong Ignatius Ou(University of California, Irvine Medical Center), Wei Hu(Blueprint Medicines (United States)), Douglas Wilson(Blueprint Medicines (United States)), Kevin Wilson(Blueprint Medicines (United States)), Lucian DiPietro(Blueprint Medicines (United States)), Jason D. Brubaker(Blueprint Medicines (United States)), Joseph L. Kim(Blueprint Medicines (United States))
Cited by 392
Related Papers
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2017|2.4k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
<i>EGFR</i> Mutations and <i>ALK</i> Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis
|Clinical Cancer Research|2016|1.2k